Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02667886 · ClinicalTrials.gov registry record · Phase 1
Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma
A Phase 1 study, sponsored by X4 Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 74
- Enrollment target
NCT02667886 is a Phase 1 study that has completed, run by X4 Pharmaceuticals. The registered enrollment target is 74 participants.
The verdict
NCT02667886, a Phase 1 study, has completed, sponsored by X4 Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 74 participants
- Enrollment target
Study Summary
The purpose of the study is to test different doses of X4P-001 given alone and in combination with axitinib in participants diagnosed with advanced renal cell carcinoma. The goals of the study are to determine the safety and tolerability of X4P-001, as well as the potential effect it may have on the body and the cancer tumor.
Interventions
- DRUG axitinib
- DRUG X4P-001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2016-04-27 |
| Est. Completion | 2022-04-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02667886
The ClinicalTrials.gov registry entry for NCT02667886 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is X4 Pharmaceuticals, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which axitinib is the first listed.
NCT02667886 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02667886 about?
NCT02667886 is a clinical study titled "Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma". The purpose of the study is to test different doses of X4P-001 given alone and in combination with axitinib in participants diagnosed with advanced renal cell carcinoma. The goals of the study are to determine the safety and tolerability of X4P-001, as well as the potential effect it may have on the...
What is the current status of trial NCT02667886?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 74 participants. The study started on 2016-04-27. Estimated completion is 2022-04-14.
What interventions are being tested in trial NCT02667886?
The interventions under investigation include: axitinib (DRUG), X4P-001 (DRUG).
Who is sponsoring clinical trial NCT02667886?
This trial is sponsored by X4 Pharmaceuticals, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.